| Literature DB >> 36231841 |
Dorota Nowosielecka1,2, Wojciech Jacheć3, Anna Polewczyk4,5, Łukasz Tułecki2, Paweł Stefańczyk1, Andrzej Kutarski6.
Abstract
"Ghosts" are fibrinous remnants that become visible during transvenous lead extraction (TLE).Entities:
Keywords: ghost; scar tissue; transoesophageal echocardiography; transvenous lead extraction
Mesh:
Substances:
Year: 2022 PMID: 36231841 PMCID: PMC9565986 DOI: 10.3390/ijerph191912542
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 4.614
Figure 1Flow chart of the recruitment process towards the study group.
Figure 2SG (red arrows) in different areas of the cardiovascular system imaged by 2D and 3D TEE. (A) SG at the SVC orifice. (B) SG leaving the RAA. (C) SG in the SVC/RA. (D) Long SG stretched between the TV and SVC. (E) Large SG in the RA adhering to the septal leaflet. (F) SG adhering to the RV endocardium.
Figure 3Concomitant occurrence of FG and SG and their fate imaged by 2D TEE (the sequences of the video and the behavior of the ghosts are represented “frame by frame”). (A) Ventricular lead (yellow arrows) dissected using the Byrd dilator sheath (green arrow). Scar tissue pushed in front of the catheter (red circle). The end piece of the lead adhered to the RA endocardium (blue arrow). (B) After lead extraction FG (red circle) in the RA and SG (blue circle) in the RV. (C) FG travelled in the bloodstream to the RV in the next heartbeat, whereas SG remained in the RA. (D) In the subsequent cardiac cycles FG „disappeared” in the pulmonary circulation, only SG remained in place.
Figure 4Flying ghosts that travelled to the systemic circulation through the PFO imaged by 2D, 3D TEE (A) Coronary sinus lead extraction (yellow arrow) (CS). Encapsulating scar tissue (red arrow) dissected away from the pacing lead using the Byrd dilator sheath (green arrow). (B) Pieces of scar tissue (FG) (red arrow) freed during lead dissection. Pulling on the cardiac wall (yellow line) during extraction of the adherent lead. (C) FG, freed from the lead, floating in the RA. (D,E) The same FG passing through the PFO. (F) FG in the LA.
Figure 5Examples of scar tissue surrounding the leads as seen after extraction (A,C,D,F) Examples of scar tissue surrounding the leads as seen after extraction (B) Calcification of the scar tissue. (E) Ossification of the scar tissue.
Patient characteristics and comparison of potential patient-related risk factors for the occurrence of both forms of ghost.
| Patient Characteristics | Flying Ghosts (Ghosts Shifting Spontaneously to Pulmonary Vascular Bed) | Stable Ghosts (Ghosts Remaining Attached to Cardiovascular Wall) | Ghosts Absent during and after TLE |
|---|---|---|---|
| Group/number of patients | 1: N = 171 (15.50%) | 2: N = 322 (29.19%) | 3: N = 610 (55.31%) |
| Form of result presentation | mean ± SD/n (%) | mean ± SD/n (%) | mean ± SD/n (%) |
| Patient age during TLE [years] | 66.06 ± 16.20 | 65.73 ± 15.29 | 68.87 ± 13.38 |
| Patient age at first system implantation [years] | 53.53 ± 18.63 | 56.21 ± 17.39 | 59.37 ± 14.81 |
| Female | 70 (40.94) | 140 (43.48) | 232 (38.03) |
| Etiology: ischemic heart disease | 109 (63.72) | 204 (63.35) | 404 (66.23) |
| NYHA III & IV | 31 (18.13) | 54 (16.77) | 98 (16.07) |
| LVEF average [%] | 48.43 ± 15.07 | 49.04 ± 14.86 | 47.93 ± 15.82 |
| LVEF category: significantly decreased (<30%) | 24 (14.04) | 40 (12.42) | 102 (16.72) |
| Permanent atrial fibrillation | 39 (22.81) | 71 (22.05) | 148 (24.26) |
| Congestive heart failure | 58 (33.92) | 84 (26.09) | 169 (27.71) |
| Renal failure (any) | 34 (19.88) | 75 (23.19) | 162 (26.56) |
| Charlson comorbidity index | 5.175 ±4.185 | 4.708 ± 3.746 | 5.090 ± 3.671 |
TLE—transvenous lead extraction, SD—standard deviation, N number, NYHA—New York Heart Association functional class, LVEF—left ventricular ejection fraction.
Factors that influenced ghost (flying or stable) occurrence during and after TLE, results of uni- and multivariable regression analysis.
| Univariable Regression | Multivariable Regression | |||||
|---|---|---|---|---|---|---|
| OR | 95% CI |
| OR | 95% CI |
| |
| Flying ghosts | ||||||
| Patient age at first system implantation | 0.977 | 0.967–0.987 | <0.001 | 0.984 | 0.970–0.997 | 0.019 |
| Systemic infection | 0.526 | 0.301–0.920 | 0.024 | 0.539 | 0.289–1.006 | 0.052 |
| Number of CIED-related procedures before TLE | 1.227 | 1.046–1.439 | 0.012 | 1.081 | 0.832–1.403 | 0.560 |
| Dwell time of the oldest target lead in the patient before TLE [by year] | 1.060 | 1.035–1.085 | <0.001 | 0.988 | 0.946–1.033 | 0.607 |
| Any form of scar tissue on the lead(s) | 10.34 | 5.625–19.02 | <0.001 | 7.106 | 3.424–14.75 | <0.001 |
| Number of separate scars | 1.685 | 1.457–1.949 | <0.001 | 1.372 | 1.076–1.749 | 0.011 |
| Lead adhesion to heart structures (any) | 2.811 | 1.961–4.028 | <0.001 | 0.517 | 0.281–0.953 | 0.034 |
| Stable ghosts | ||||||
| Patient age at first system implantation | 0.989 | 0.985–0.993 | <0.001 | 0.989 | 0.980–0.999 | 0.030 |
| Charlson comorbidity index | 0.976 | 0.940–1.013 | 0.197 | |||
| Abandoned lead before TLE | 1.883 | 1.207–2.938 | 0.005 | 1.152 | 0.653–2.032 | 0.623 |
| Number of leads in the heart before TLE | 1.554 | 1.280–1.887 | <0.001 | 1.450 | 1.141–1.842 | 0.002 |
| Number of CIED-related procedures before lead extraction | 1.127 | 0.981–1.296 | 0.092 | 0.940 | 0.786–1.124 | 0.499 |
| All forms of scar tissue on the lead(s) | 2.304 | 1.708–3.106 | <0.001 | 1.940 | 1.293–2.909 | <0.001 |
| Number of separate scars | 1.424 | 1.260–1.609 | <0.001 | 1.147 | 0.939–1.403 | 0.179 |
| Lead adhesion to heart structures (any) | 1.699 | 1.252–2.307 | <0.001 | 1.045 | 0.658–1.660 | 0.851 |
TLE—transvenous lead extraction, CIED—cardiac implantable electronic device.
Long term and 30-d survival after TLE.
| Long Term and 30-Days Survival after TLE | Flying Ghosts (Ghosts Shifting Spontaneously to Pulmonary Vascular Bed) | Stable Ghosts (Ghosts Remaining Attached to Cardiovascular Wall) | Ghosts Absent during and after TLE |
|---|---|---|---|
| Group/number of patients | 1: N = 171 | 2: N = 322 | 3: N = 610 |
| Long-term survival of entire group of patients after TLE during mean 1264 ± 644.7 (2–2466) days follow-up. Log rank | |||
| Follow-up (mean ± SD) [days] | 1048 ± 417.5 | 1511 ± 588.0 | 1544 ± 555.0 |
| Alive during follow-up (entire group) | 143 (83.63) | 242 (75.16) | 437 (71.64) |
| Died during follow-up (entire group) | 28 (16.37) | 80 (24.84) | 173 (28.36) |
| Long-term survival after TLE in the subgroup of non-infectious and infectious patients. Log rank | |||
| Non-infectious; died/alive | 19/131 (12.67) | 41/200 (17.01) Log rank test | 114/360 (24.05) Log rank test |
| Infectious (all); died/alive | 9/12 (42,86) | 39/42 (48.15) | 59/77 (43.38) |
| Long-term survival after TLE in subgroup of patients with pocket infection. Log rank | |||
| Local (pocket) infection; died/alive | 2/4 (33.33) | 8/10 (44.44) Log rank test | 11/27 (28.95) |
| Long term survival after TLE in subgroup of patients with systemic. Log rank | |||
| Systemic infection; died/alive | 7/8 (46.67) | 31/32 (49.21) Log rank test | 48/50 (48.98) |
| 30-days survival after TLE in entire group of patients | |||
| Entire group; died/alive | 2/169 (1.17) | 7/315 (2.17) | 10/600 (1.64) |
| 30-days survival after TLE in subgroup of non-infectious patients | |||
| Non-infectious; died/alive | 2/148 (1.33) | 2/239 (0.83) | 4/470 (0.84) |
| Infectious (all); died/alive | 0/21 (0.00) | 5/76 (6.17) | 6/130 (4.41) |
| 30-days survival after TLE in subgroup of patients with pocket infection | |||
| Local (pocket) infection; died/alive | 0/6 (0.00) | 0/18 (0.00) | 0/38 (0.00) |
| Long term survival after TLE in subgroup of patients with systemic infection | |||
| Systemic infection; died/alive | 0/15 (0.00) | 5/58 (7.94) | 6/92 (6.12) |
TLE—transvenous lead extraction, SD—standard deviation.
Figure 6Kaplan–Meier probability of survival after TLE based on the presence of ghosts during or after TLE.
Factors influencing long-term prognosis after TLE, results of uni- and multivariable Cox regression analysis.
| Univariable Cox Regression | Multivariable Cox Regression | |||||
|---|---|---|---|---|---|---|
| HR | 95% |
| HR | 95% |
| |
| All patients | ||||||
| Female gender | 0.441 | 0.336–0.579 | <0.001 | 0.621 | 0.463–0.833 | <0.001 |
| Patient age during TLE [by year] | 1.049 | 1.038–1.061 | <0.001 | 1.040 | 1.025–1.054 | <0.001 |
| NYHA FC class [by one] | 2.914 | 2.410–3.523 | <0.001 | 1.526 | 1.197–1.946 | <0.001 |
| LVEF [by 1p%] | 0.966 | 0.958–0.973 | <0.001 | 0.987 | 0.981–0.978 | 0.009 |
| Renal failure (any) | 3.269 | 2.587–4.131 | <0.001 | 1.599 | 1.243–2.058 | 0.001 |
| Ischemic heart disease | 1.457 | 1.125–1.887 | 0.004 | 1.014 | 0.758–1.355 | 0.927 |
| Permanent atrial fibrillation | 2.372 | 1.866–3.015 | <0.001 | 1.443 | 1.122–1.856 | 0.004 |
| Charlson comorbidity index | 1.142 | 1.111–1.174 | <0.001 | 1.044 | 1.010–1.080 | 0.012 |
| Flying ghosts (1st group) | 0.795 | 0.537–1.178 | 0.252 | |||
| Stable ghosts (2nd group) | 0.881 | 0.680–1.141 | 0.336 | |||
| Ghosts absent (3rd group) | 1.223 | 0.962–1.555 | 0.100 | |||
| ICD presence before TLE | 1.156 | 0.884–1.512 | 0.292 | |||
| Device type: CRTP/CRTD | 3.125 | 2.382–4.100 | <0.001 | 1.702 | 1.248–2.322 | <0.001 |
| Systemic infection | 2.854 | 2.220–3.667 | <0.001 | 1.894 | 1.460–2.457 | <0.001 |
| Isolated pocket infection | 1.281 | 0.829–1.979 | 0.265 | |||
| Infectious patients | ||||||
| Female gender | 0.485 | 0.301–0.780 | 0.003 | 0.578 | 0.347–0.964 | 0.036 |
| Patient age during TLE [by year] | 1.027 | 1.009–1.045 | 0.003 | 1.037 | 1.014–1.061 | 0.002 |
| NYHA FC class [by one] | 2.278 | 1.687–3.075 | <0.001 | 1.659 | 1.118–2.462 | 0.012 |
| LVEF [by 1p%] | 0.969 | 0.957–0.981 | <0.001 | 0.988 | 0.972–1.004 | 0.133 |
| Renal failure (any) | 2.512 | 1.729–3.649 | <0.001 | 1.686 | 1.136–2.503 | 0.009 |
| Ischemic heart disease | 0.938 | 0.620–1.421 | 0.764 | |||
| Permanent atrial fibrillation | 1.642 | 1.106–2.438 | 0.014 | 1.010 | 0.657–1.552 | 0.965 |
| Charlson comorbidity index | 1.096 | 1.047–1.147 | <0.001 | 1.025 | 0.972–1.082 | 0.363 |
| Flying ghosts (1st group) | 1.089 | 0.548–2.163 | 0.807 | |||
| Stable ghosts (2nd group) | 1.041 | 0.705–1.536 | 0.841 | |||
| Ghosts absent (3rd group) | 0.940 | 0.645–1.369 | 0.747 | |||
| Device type: ICD | 1.018 | 0.666–1.556 | 0.935 | |||
| Device type: CRTP/CRTD | 2.783 | 1.861–4.161 | <0.001 | 1.766 | 1.087–2.868 | 0.022 |
| Isolated pocket infection | 0.560 | 0.351–0.894 | 0.015 | 1.083 | 0.581–2.018 | 0.801 |
| Vegetations presence | 1.620 | 1.094–2.399 | 0.016 | 1.405 | 0.835–2.365 | 0.201 |
| Non-infectious patients | ||||||
| Female gender | 0.478 | 0.342–0.669 | <0.001 | 0.638 | 0.443–0.919 | 0.016 |
| Patient age during TLE [by year] | 1.056 | 1.040–1.071 | <0.001 | 1.043 | 1.024–1.062 | 0.000 |
| NYHA FC class [by one] | 3.140 | 2.439–4.043 | <0.001 | 1.619 | 1.165–2.249 | 0.004 |
| LVEF [by 1p%] | 0.965 | 0.956–0.975 | <0.001 | 0.988 | 0.975–1.000 | 0.048 |
| Renal failure (any) | 3.356 | 2.483–4.535 | <0.001 | 1.489 | 1.072–2.068 | 0.017 |
| Ischemic heart disease | 1.602 | 1.151–2.230 | 0.005 | 0.882 | 0.618–1.258 | 0.488 |
| Permanent atrial fibrillation | 2.815 | 2.078–3.814 | <0.001 | 1.693 | 1.236–2.320 | 0.001 |
| Charlson comorbidity index | 1.148 | 1.108–1.190 | <0.001 | 1.058 | 1.013–1.105 | 0.011 |
| Flying ghosts (1st group) | 0.822 | 0.509–1.330 | 0.425 | |||
| Stable ghosts (2nd group) | 0.721 | 0.508–1.024 | 0.068 | 1.103 | 0.633–1.923 | 0.728 |
| Ghosts absent (3rd group) | 1.428 | 1.043–1.954 | 0.026 | 1.352 | 0.821–2.226 | 0.236 |
| Device type: ICD | 1.162 | 0.820–1.645 | 0.398 | |||
| Device type: CRTP/CRTD | 2.758 | 1.895–4.015 | <0.001 | 1.684 | 1.126–2.520 | 0.011 |
TLE—transvenous lead extraction, NYHA FC—New York Heart Association functional class, LVEF—left ventricular ejection fraction, ICD—implantable cardioverter defibrillator, CRTP—cardiac resynchronisation therapy pacemaker, CRTD—cardiac resynchronisation therapy defibrillator.